NASDAQ:ORIC ORIC Pharmaceuticals (ORIC) Stock Price, News & Analysis $11.90 +0.66 (+5.87%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$11.40▼$12.0950-Day Range$6.63▼$11.2652-Week Range$5.27▼$16.65Volume658,349 shsAverage Volume550,449 shsMarket Capitalization$802.30 millionP/E RatioN/ADividend YieldN/APrice Target$19.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get ORIC Pharmaceuticals alerts: Email Address ORIC Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside63.9% Upside$19.50 Price TargetShort InterestBearish16.88% of Shares Sold ShortDividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews Sentiment0.70Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.68) to ($1.89) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.31 out of 5 starsMedical Sector153rd out of 936 stocksPharmaceutical Preparations Industry62nd out of 436 stocks 4.5 Analyst's Opinion Consensus RatingORIC Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageORIC Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about ORIC Pharmaceuticals' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted16.88% of the outstanding shares of ORIC Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverORIC Pharmaceuticals has a short interest ratio ("days to cover") of 20.9, which indicates bearish sentiment.Change versus previous monthShort interest in ORIC Pharmaceuticals has recently decreased by 2.74%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldORIC Pharmaceuticals does not currently pay a dividend.Dividend GrowthORIC Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreORIC Pharmaceuticals has received a 72.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for ORIC Pharmaceuticals is -0.77. Previous Next 3.2 News and Social Media Coverage News SentimentORIC Pharmaceuticals has a news sentiment score of 0.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for ORIC Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest2 people have searched for ORIC on MarketBeat in the last 30 days. MarketBeat Follows2 people have added ORIC Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ORIC Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.55% of the stock of ORIC Pharmaceuticals is held by insiders.Percentage Held by Institutions95.05% of the stock of ORIC Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ORIC Pharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for ORIC Pharmaceuticals are expected to decrease in the coming year, from ($1.68) to ($1.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ORIC Pharmaceuticals is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ORIC Pharmaceuticals is -6.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioORIC Pharmaceuticals has a P/B Ratio of 3.57. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ORIC Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About ORIC Pharmaceuticals Stock (NASDAQ:ORIC)ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.Read More ORIC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ORIC Stock News HeadlinesJuly 24 at 7:30 AM | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: HCA Healthcare (HCA), Oric Pharmaceuticals (ORIC) and GoodRx Holdings (GDRX)July 24 at 2:40 AM | americanbankingnews.comORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives $19.50 Average Target Price from AnalystsJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 22, 2024 | tmcnet.comWilson Sonsini Expands Corporate Practice as Compensation and Benefits Partner Brandon Gantus Rejoins the FirmJuly 19, 2024 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up to $10.99July 18, 2024 | americanbankingnews.comORIC Pharmaceuticals (NASDAQ:ORIC) Earns Outperform Rating from WedbushJuly 18, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for ORIC Pharmaceuticals (NASDAQ:ORIC)July 17, 2024 | seekingalpha.comORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield ValueJuly 27, 2024 | Crypto Swap Profits (Ad)625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.July 16, 2024 | globenewswire.comORIC Pharmaceuticals Announces Multiple Clinical Collaborations with Strategic Partners to Support Ongoing Trial Evaluating ORIC-944 in Combination with AR Inhibitors for the Treatment of Prostate CancerJuly 8, 2024 | insidermonkey.comWhy Is ORIC Pharmaceuticals, Inc. (ORIC) Among the Most Shorted Stocks That Are Loved by Analysts?July 5, 2024 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 7, 2024 | globenewswire.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)May 29, 2024 | globenewswire.comORIC Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 26, 2024 | benzinga.comORIC Pharmaceuticals Stock (NASDAQ:ORIC), Insider Trading ActivityMay 8, 2024 | markets.businessinsider.comBuy Rating on Oric Pharmaceuticals Amidst Strong Financials and Promising Clinical PipelineMay 8, 2024 | morningstar.comORIC Pharmaceuticals IncMay 8, 2024 | finance.yahoo.comWe Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business GrowthSee More Headlines Receive ORIC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ORIC Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/06/2024Today7/26/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ORIC CUSIPN/A CIK1796280 Webwww.oricpharma.com Phone650-388-5600FaxN/AEmployees80Year FoundedN/APrice Target and Rating Average Stock Price Target$19.50 High Stock Price Target$27.00 Low Stock Price Target$14.00 Potential Upside/Downside+63.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-100,700,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-38.08% Return on Assets-34.82% Debt Debt-to-Equity RatioN/A Current Ratio21.31 Quick Ratio21.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.33 per share Price / Book3.57Miscellaneous Outstanding Shares67,420,000Free Float63,680,000Market Cap$802.30 million OptionableOptionable Beta1.14 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Richard A. Heyman Ph.D. (Age 67)Co-Founder, Independent Chairman & Member of Scientific Advisory Board Comp: $93kDr. Jacob M. Chacko M.B.A. (Age 45)M.D., President, CEO & Director Comp: $961kMr. Dominic G. Piscitelli CPA (Age 49)M.B.A., Chief Financial Officer Comp: $654.74kDr. Pratik S. Multani M.D. (Age 57)M.S., Chief Medical Officer Comp: $715.22kDr. Charles L. Sawyers B.A. (Age 65)M.D., Ph.D., Co-Founder & Member of Scientific Advisory Board Dr. Scott W. Lowe Ph.D.Co-Founder & Member of Scientific Advisory BoardDr. Lori Sickels Friedman Ph.D. (Age 60)Chief Scientific Officer Dr. Christian V. Kuhlen Esq. (Age 51)J.D., M.D., General Counsel Mr. Daniel IazzettiVP & Head of PeopleDr. Edna Chow Maneval (Age 64)Senior Vice President of Clinical Development More ExecutivesKey CompetitorsPhathom PharmaceuticalsNASDAQ:PHATArcutis BiotherapeuticsNASDAQ:ARQTInnate PharmaNASDAQ:IPHAKaryopharm TherapeuticsNASDAQ:KPTIBioXcel TherapeuticsNASDAQ:BTAIView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 71,394 shares on 7/26/2024Ownership: 0.277%Hennion & Walsh Asset Management Inc.Bought 102,434 shares on 7/20/2024Ownership: 0.152%Virtu Financial LLCBought 16,372 shares on 5/20/2024Ownership: 0.024%California State Teachers Retirement SystemSold 2,501 shares on 5/16/2024Ownership: 0.006%Price T Rowe Associates Inc. MDBought 915,175 shares on 5/15/2024Ownership: 2.324%View All Insider TransactionsView All Institutional Transactions ORIC Stock Analysis - Frequently Asked Questions How have ORIC shares performed this year? ORIC Pharmaceuticals' stock was trading at $9.20 on January 1st, 2024. Since then, ORIC stock has increased by 29.3% and is now trading at $11.90. View the best growth stocks for 2024 here. How were ORIC Pharmaceuticals' earnings last quarter? ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) issued its quarterly earnings results on Monday, May, 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.07. When did ORIC Pharmaceuticals IPO? ORIC Pharmaceuticals (ORIC) raised $75 million in an IPO on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO. Who are ORIC Pharmaceuticals' major shareholders? Top institutional investors of ORIC Pharmaceuticals include Bank of New York Mellon Corp (0.28%) and Hennion & Walsh Asset Management Inc. (0.15%). Insiders that own company stock include Jacob Chacko, Pratik S Multani, Richard A Heyman and Dominic Piscitelli. View institutional ownership trends. How do I buy shares of ORIC Pharmaceuticals? Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of ORIC Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ORIC Pharmaceuticals investors own include Pfizer (PFE), Intel (INTC), CrowdStrike (CRWD), Valero Energy (VLO), Hello Group (MOMO), ONEOK (OKE) and DocuSign (DOCU). This page (NASDAQ:ORIC) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ORIC Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ORIC Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
